

梁麗嫻



職稱: 澳門科技大學, 副教授,
澳門藥物及健康應用研究, 助理院長
埃爾文內爾博士生物物理與創新藥物實驗室, 執行主任

學院/部門: 中醫藥學院
中藥質量研究國家重點實驗室
埃爾文內爾博士生物物理與創新藥物實驗室

電郵地址: lhleung@must.edu.mo

電話: (853) 8897-2409

傳真: (853) 2888-0091

辦公室: H701

郵寄地址: 澳門氹仔偉龍馬路 澳門科技大學

簡介

梁麗嫻博士於 2001 年在香港中文大學分子生物技術學系取得學士學位, 並於 2003 年及 2006 年同校生物化學系及醫學院生理系分別取得碩士及博士學位, 隨後于香港大學李嘉誠醫學院病理學系及香港浸會大學中醫藥學院當博士後研究員, 從事關於肺癌的博士後研究工作。現為澳門科技大學中藥品質研究國家重點實驗室副教授, 澳門藥物及健康應用研究院助理院長。研究方向主要為肺癌靶向治療的中藥新藥研究。此外, 梁博士也致力於肺癌早期診斷及個性化醫學研究。研究成果發表在 Nature (Outlook)、Pharmacol Ther, Briefing Bioinform, Int J of Cancer, Leukemia, Oncogene, ARS, Cell Death Dis 等國際重要期刊上已發表 SCI 論文 123 篇, 其中第一作者文章 18 篇, 通訊作者文章 60 篇, 累積影響因數 (IF) 為 455.699, 影響因數 > 5 的有 11 篇, 最高影響因數為 712, 他引次數 4305, 單篇最高他引次數 825。獲國際發明授權專利 39 項。研究獲得澳門基金會, 澳門科學技術發展基金及中華人民共和國科學技術部與科學技術發展基金聯合科研資助專案等多項資助。分別在 2014 及 2018 年獲得國家教育部自然科學獎一等獎 (第五排名人), 國家科技部與澳門科技發展基金聯合課題 (2014) 及國家自然科學基金海外及港澳學者合作研究基金專案 (2018)。2013 年獲中銀學術研究優秀獎, 於 2014 年和 2018 年兩次獲澳門科學技術自然科學類一等獎, 2020 年獲國家中醫藥管理局授予青年岐黃學者稱號。受邀任國際知名藥理學雜誌 Pharmacol Res (IF 5.574, Q1 區間) 中藥及天然產物藥理刊部副主編, 是兩岸四地唯一受邀任此職位的學者。

教研領域

生物化學; 現代生物技術; 藥理實驗方法學; 中藥學研究進展; 臨床藥理學; 專業英語

學歷

2006.07 香港中文大學博士學位
2003.08 香港中文大學碩士學位
2001.08 香港中文大學學士學位

教學經驗

2019.9-今 澳門科技大學埃爾文內爾博士生物物理與創新藥物實驗室 / 執行主任
2015.9-今 澳門科技大學 / 副教授
澳門科技大學澳門藥物及健康應用研究院 / 助理院長
湖北省太和醫院 / 訪問教授
2017.10-今 廣州醫科大學附屬第一醫院 / 兼職教授
2017.11-今 項目顧問 / 強生製藥公司

學術成果

期刊文章:

SCI 期刊論文:

1. Song Q, He X, Xiong Y, Wang J, Zhang L, **Leung EL***, Li G*. The functional landscape of Golgi membrane protein 1 (GOLM1) phosphoproteome reveal GOLM1 regulating P53 that promotes malignancy. Cell Death Discovry.2021 Mar 01;71(1)
2. Shen C, Weng G, Zhang X, **Leung EL**, Yao X, Pang J, Chai X, Li D, Wang E, Cao D, Hou T. Accuracy or novelty: what can we gain from target-specific machine-learning-based scoring functions in virtual screening?. Briefings Bioinformatics.2021 Jan 08
3. Wu Z, Zhu M, Kang Y, **Leung EL**, Lei T, Shen C, Jiang D, Wang Z, Cao D, Hou T. Do we need different machine learning algorithms for QSAR modeling? A comprehensive assessment of 16 machine learning algorithms on 14 QSAR data sets. Briefings Bioinformatics.2020 Dec 14
4. Wang Y, Tang S, Lai H, Jin R, Long X, Li N, Tang Y, Guo H, Yao X*, **Leung EL***. Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening. Frontiers in Pharmacology.2020 Nov 11;11:1583.
5. Jiang JB, Huang JM, Xie YJ, Zhang YZ, Chan C, Lai HL, Wang WJ, Yao XJ, Fan XX, Wu QB, Xie C, Wang MF*, **Leung EL***. Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. Journal of Experimental & Clinical Cancer Research.2020 Dec;39(1):1-6.
6. Xie Y#, Meng WY#, Li RZ#, Wang YW, Qian X, Chan C, Yu ZF, Fan XX, Pan HD, Xie C, Wu QB, Yan PY, Liu L, Tang YJ, Yao XJ*, Wang MF* and **Leung EL***. Early lung cancer diagnostic biomarker discovery by machine learning methods. Translational Oncology.2020 Nov 17;14(1):100907.
7. Zhang YZ#, Lai HL#, Chen PP#, Li D, Khan I, Hsiao WL, Fan XX, Yao XJ, Wu QB*, Wang MF* & **Leung EL***. Clinical significance of LSEctin and its

- association with PVR in non-small-cell lung cancer patients. *Annals of Translational Medicine*.2020 Nov;8(21).
8. Lai HL#, Fan XX#, Liu RZ#, Wang YW, Zhang JM, Liu L, Neher E*, Yao XJ* and **Leung EL***. Roles of ion fluxes, metabolism, and redox balance in cancer therapy. *Antioxidants and redox signaling*.2020 Oct 29(ja).
 9. Liu Y, Wang M, Luo G, Qian X, Wu C, Zhang Y, Chen B, **Leung EL***, Tang Y*. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19. *Medicine*.2020 Oct 16;99(42).
 10. **Leung EL#**, Lai HL#, Li RZ, Pan HD, Jiang ZB Li Y, Duan FG, Xu JH, Zhang YZ, Shi AX, Wei CL, Zhang FY, Yao XJ and Liang Liu. Roles of serum amyloid A1 protein isoforms in rheumatoid arthritis. *Engineering*.2020
 11. Wu QB*, Yao XJ, Chen HW, Li T, Fan XX, Zhang GL, Yu LL, Chen M, Xu C, Zhang RN, Chen B, Sui XB*, **Leung EL***. Long-term aspirin use for primary cancer prevention: An updated systematic review and subgroup meta-analysis of 29 randomized clinical trials. *Journal of Cancer*.2020;11(21):6460.
 12. **Leung EL**, Pan HD, Huang YF, Fan XX, Wang WY, He F, Cai J, Zhou H, Liu L. The scientific foundation of Chinese herbal medicine against COVID-19. *Engineering*.2020 Oct;610(10)
 13. **Leung EL***, Xu S*. Traditional Chinese Medicine in Cardiovascular Drug Discovery. *Pharmacological Research*.2020 Oct 1;160:105168.
 14. Wang WJ, Mao LF, Lai HL, Wang YW, Jiang ZB, Li W, Huang JM, Xie YJ, Xu C, Liu P, Li YM, **Leung EL***, Yao XJ*. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway. *Pharmacological Research*.2020 Nov 1;161:105129.
 15. Liu H, Zheng J, Lai HC, Hu B, Zhu L, **Leung EL***, Wei H*. Microbiome technology empowers the development of traditional Chinese medicine. *Sci China Life Sci*.2020 Nov;63(11):1759-61.
 16. Chen B, Zhang RN, Fan X, Wang J, Xu C, An B, Wang Q, Wang J, **Leung EL***, Sui X*, Wu Q*. Clinical diagnostic value of long noncoding RNAs in colorectal Cancer: A systematic review and meta-analysis. *Journal of Cancer*.2020;11(18):5518.
 17. Hussain S, Xie YJ, Li D, Malik SI, Hou JC, **Leung EL***, Fan XX*. Current strategies against COVID-19. *Chinese Medicine*.2020 Dec;15(1):1-2.
 18. Wang Z, Wu W, Guan X, Guo S, Li C, Niu R, Gao J, Jiang M, Bai L, **Leung EL**, Hou Y, Jiang Z, Bai G. 20 (S)-protopanaxatriol promotes the binding of P53 and DNA to regulate the antitumor network via multiomic analysis. *Acta Pharmaceutica Sinica B*.2020 Feb 5.
 19. Huang J, Jiang Z, Wang Y, Fan X, Cai J, Yao X, Liu L, Huang J, He J, Xie C, Wu Q*, Cao Y*, **Leung EL***. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. *Current Opinion in Pharmacology*.2020 Oct 1;54:1-0.

20. Luo S, Xu J, Jiang Z, Liu L, Wu Q, **Leung EL***, Leung AP*. Artificial Intelligence-Based Collaborative Filtering Method with Ensemble Learning for Personalized Lung Cancer Medicine without Genetic Sequencing. *Pharmacological Research*.2020 Oct 1;160:105037.
21. Hu B, Ye C, **Leung EL**, Zhu L, Hu H, Zhang Z, Zheng J, Liu H. Bletilla striata oligosaccharides improve metabolic syndrome through modulation of gut microbiota and intestinal metabolites in high fat diet-fed mice. *Pharmacological Research*.2020 Jun 3:104942.
22. Xie YJ, Gao WN, Wu QB, Yao XJ, Jiang ZB, Wang YW, Wang WJ, Li W, Hussain S, Liu L, **Leung EL***, Fan XX*. Chelidonine Selectively Inhibits the Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells through the EGFR-AMPK Pathway. *Pharmacological Research*.2020 May 25:104934.
23. Huang F, Li Y, **Leung EL**, Liu X, Liu K, Wang Q, Lan Y, Li X, Yu H, Cui L, Luo H, Luo L. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). *Pharmacological Research*.2020 May 20:104929.
24. Zheng Y, Xiong C, Liu Y, Qian X, Tang Y, Liu L, **Leung EL**, Wang M. Epidemiological and Clinical Characteristics Analysis of COVID-19 in the Surrounding Areas of Wuhan, Hubei Province in 2020. *Pharmacological Research*.2020 Apr 30:104821.
25. Song Q, Zhang J, Wu Q, Li G*, **Leung EL***. Kanglaite injection plus Fluorouracil-based chemotherapy on the reduction of adverse effects and improvement of clinical effectiveness in patients with advanced malignant tumors of the digestive tract: A meta-analysis of 20 RCTs following the PRISMA guidelines. *medicine*.2020 Apr 1;99(17):e19480.
26. You H, Zhang YZ, Lai HL, Li D, Liu YQ, Li RZ, Khan I, Hsiao WW, Duan FG, Fan XX, Yao XJ, Cao YB, Wu QB*, **Leung EL***, Wang MF*. Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer. *Journal of Cancer Research and Clinical Oncology*.2020 Apr 4:1-0.
27. Yan LE, Zhang HY, Wada M, Fang L, Feng J, Zhang WL, Chen Q, Cao YZ, Pinz KG, Chen KH, Petrov JC, Chen X, **Leung EL**, Fan XX, Senzel L, Jiang X, Ma YP. Targeting two antigens associated with B-all with CD19-CD123 compound CART cell therapy. *Stem Cell Reviews and Reports*.2020 Jan 22:1-2.
28. **Leung EL*** & Wu QB*. Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk. *JAMA Oncology*.2020 May 1;6(5):788-.
29. Xu C, Yao XJ, Li T, Wang J, Sue XB, **Leung EL*** and Wu QB*. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer. *Translational Cancer Research*.2020 Apr 1;9(4):2875-83.
30. Fan XX, Xu MZ, **Leung EL**, Cai J, Yuan Z & Liu L. ROS-Responsive Berberine Polymeric Micelles Effectively Suppressed the Inflammation of Rheumatoid

- Arthritis by Targeting Mitochondria. *Nano-Micro Letters*.2020 Mar;12(1):1-4.
31. Mok SW, Wong VK, Lo HH, de Seabra Rodrigues Dias IR, **Leung EL**, Law BY, Liu L. Natural products-based polypharmacological modulation of the peripheral immune system for the treatment of neuropsychiatric disorders. *Pharmacology & Therapeutics*.2020 Apr 1;208:107480.
 32. Liu Y, Chen X, Choi YJ, Yang N, Song Z, Snedecor ER, Liang W, **Leung EL**, Zhang L, Qin C, Chen J. GORAB promotes embryonic lung maturation through antagonizing AKT phosphorylation, versican expression and mesenchymal cell migration. *FASEB Journal*.2020 Apr;34(4):4918-33.
 33. Chen H, Yao X, Li T, Lam CW, Zhang R, Zhang H, Wang J, Zhang W, **Leung EL***, Wu Q*. Compound Kushen injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 37 RCTs following the PRISMA guidelines. *Journal of Cancer*.2020;11(7):1883.
 34. **Leung EL*** & Wu QB*. Commentary on Ge et al. “Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. *Sleep Medicine Reviews*.2020 Jan 8;50:101257.
 35. Li JX, Huang JM, Jiang ZB, Li RZ, Sun A, **Leung EL*** & Yan PY*. Current clinical progress of PD-1/PD-L1 immunotherapy and potential combination treatment in non-small cell lung cancer. *INTEGRATIVE CANCER THERAPIES*.2019 Dec;18:1534735419890020.
 36. Ren T#, Fan XX#, Wang MF#, Duan FG, Wei CL, Li RZ, Jiang ZB, Wang YW, Yao XJ, Chen MW, Tang YJ*, **Leung EL***. miR - 20b promotes growth of non - small cell lung cancer through a positive feedback loop of the Wnt/ β - catenin signaling pathway. *International Journal of Oncology*.2020 Feb 1;56(2):470-9.
 37. Chen H#, Yao X#, Li T, Lam CW, Zhang H, Wang J, Zhang W, **Leung EL***, Wu Q*. Compound Kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A protocol for meta-analysis of randomized clinical trials following the PRISMA guidelines. *Medicine (Baltimore)*.2019 Dec;98(52).
 38. **Leung EL*** & Wu QB*. The evidence strength of a meta-analysis of aspirin for primary prevention of cancer. *Journal of Cancer Research and Clinical Oncology*.2020 Aug;146(8):2173-5.
 39. Duan FG#, Wang MF#, Cao YB, Dan Li, Li RZ, Fan XX, Khan I, Lai HL, Zhang YZ, Hsiao WW, Yao XJ, Wu QB, Liu L*, Tang YJ*, **Leung EL***. MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3'UTR and predicts poor survival in non-small cell lung cancer. *Cell Death & Disease*.2019 Oct 28;10(11):1-4.
 40. Wang Y#, Tang C#, Yao S, Lai H, Li R, Xu J, Wang Q, Fan XX, Wu QB, **Leung EL***, Ye Y*, Yao X*. Discovery of a novel protein kinase C activator from *Croton tiglium* for inhibition of non-small cell lung cancer. *Phytomedicine*.2019

41. Chen H#, Yao X#, Liu Z#, Li T, Xu C, Wang J, Sui X*, **Leung EL***, Wu Q*. Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)*.2019 Sep;98(39).
42. Wu Q*, Chen H, Yao X, Li T, Xu C, Wang J, Sui X*, **Leung EL***. Long-term aspirin use for cancer primary prevention: A protocol for updated systematic review and subgroup meta-analysis of randomized clinical trials. *Medicine (Baltimore)*.2019 Sep;98(39).
43. Pan HD#, Xiao Y#, Wang WY, Ren RT, **Leung EL*** & Liu L*. Traditional Chinese Medicine as a Treatment for Rheumatoid Arthritis-From Empirical Practice to Evidence-based Therapy. *Engineering*.2019 Oct 1;5(5):895-906.
44. Zhang J#, Yang C#, Wei D#, Li H#, **Leung EL**, Deng Q, Liu Z, Fan XX*, Zhang Z*. Long-term efficacy of Chinese medicine Bushen Capsule on cognition and brain activity in patients with amnesic mild cognitive impairment. *Pharmacological Research*.2019 Aug 1;146:104319.
45. Zhang Y#, Han CY#, Duan FG, Fan XX, Yao XJ, Parks RJ, Tang YJ, Wang MF, Liu L, Tsang BK*, **Leung EL***. p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. *Cancer Cell International*.2019 Dec;19(1):188.
46. Pan H, Guo R, Ju Y, Wang Q, Zhu J, Xie Y, Zheng Y, Li T, Liu Z, Lu L, Li F, Tong B, Xiao L, Xu X, **Leung EL**, Li R, Yang H, Wang J, Zhou H, Jia H, Liu L. A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. *Microbiome*.2019 Dec 1;7(1):107.
47. Jin N#, Bi A#, Lan X#, Xu J, Wang X, Liu Y, Wang T, Tang S, Zeng H, Chen Z, Tan M, Ai J, Xie H, Zhang T, Liu D, Huang R, Song Y, **Leung EL**, Yao X, Ding J, Geng M*, Lin SH*, Huang M*. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. *Nature communications*.2019 Jun 20;10(1):1-5.
48. Tian G#, Wu C#, Li J#, Liang B#, Zhang F, Fan X, Li Z, Wang Y, Li Z*, Liu D*, **Leung EL***, Chen J*. Network pharmacology based investigation into the effect and mechanism of Modified Sijunzi Decoction against the subtypes of chronic atrophic gastritis. *Pharmacological Research*.2019 Jun 1;144:158-66.
49. Xu JH#, Wang QQ#, **Leung EL#**, Li Y, Fan XX, Wu QB*, Yao XJ* & Liu Liang*. Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin remodeling factor in non-small cell lung cancer. *Frontiers of Medicine*.2020 Feb;14(1):60-7.
50. Wei CL, Zhang DZ, Cheng JL, Chen X, Fan XX, Xie C, Yao XJ, Wang YW, Jiang ZB, Fu JZ* and **Leung EL***. Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. *Pharmacological Research*.2019 Jun 1;144:79-89.

51. **Leung EL#**, Luo LX#, Li Y, Liu ZQ, Li LL, Shi DF, Xie Y, Huang M, Lu LL, Duan FG, Huang JM, Fan XX, Yuan ZW, Ding J, Yao XJ*, Ward DC* & Liu L* . Identification of a new inhibitor of KRAS-PDE δ interaction targeting KRAS mutant non-small cell lung cancer. *International journal of cancer*.2019 Sep 1;145(5):1334-45.
52. **Leung EL*** & Wu QB*. Concurrent use of herbal products with prescription drugs is a double-edged sword and evidence-based medicine contributes to reshaping the practice. *Pharmacological Research*.2017;2:101-7.
53. Wang QQ, An X, Wang YW, Liu L*, **Leung EL*** and Yao XJ*. Classical molecular dynamics and metadynamics simulations decipher the mechanism of CBP30 selectively inhibiting CBP/p300 bromodomains. *Organic & biomolecular chemistry*.2018;16(35):6521-30.
54. Fan XX#, Pan HD#, Li Y, Guo RJ, **Leung EL***, Liu L*. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. *Pharmacology & therapeutics*.2018 Nov 1;191:148-61.
55. Wang Q, Li Y, Xu J, Wang Y, Shi D, Liu L*, **Leung EL***, Yao X*. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4. *PROTEINS-STRUCTURE FUNCTION AND GENETICS*.2019 Jan;87(1):3-11.
56. Lai HL, Wang YW, Li Y, Jiang ZB, Duan FG, Luo LX, Liu L*, **Leung EL*** and Yao XJ*. Krukovine suppresses KRAS-mutated lung cancer cell growth and proliferation by inhibiting the RAF-ERK pathway and inactivating AKT. *Frontiers in Pharmacology*.2018 Aug 22;9:958.
57. Wang YW, Lai HL, Fan XX, Luo LX, Duan FG, Jiang ZB, Wang QQ, **Leung EL***, Liu L*, Yao XJ*. Gossypol inhibits non-small cell lung cancer cells proliferation by targeting EGFR L858R/T790M. *Frontiers in Pharmacology*.2018 Jul 9;9:728.
58. Li RZ, Fan XX, Shi DF, Zhu GY, Wang YW, Luo LX, Pan HD, Yao XJ*, **Leung EL*** & Liu L*. Identification of a new Pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small cell lung cancer (NSCLC). *Chemical Biology & Drug Design*.2018 Nov;92(5):1851-8.
59. Li RZ#, Fan XX#, Duan FG, Jiang ZB, Pan HD, Luo LX, Zhou YL, Li Y, Yao YJ, **Leung EL*** & Liu L*. Proscillaridin A induces apoptosis and suppresses non-small cell lung cancer tumor growth via calcium-induced DR4 up-regulation. *Cell Death & Disease*.2018 Jun 13;9(6):1-4.
60. Wei C, Yang L, Cheng J, Imani S, Fu S, Lv H, Li Y, Chen R, **Leung EL***, Fu J*. A novel homozygous variant of GPR98 causes usher syndrome type IIC in a consanguineous Chinese family by next generation sequencing. *BMC Medical Genetics*.2018 Dec;19(1):1-8.
61. Liu XY, Yang KY, Wang MQ, Kwok JS, Zeng X, Yang Z, Xiao XJ, Lau CP, Li Y, Huang ZM, Ba JG, Yim AK, Ouyang CY, Ngai SM, Chan TF, **Leung EL**, Liu L, Liu ZG, Tsui SKW. High-quality assembly of *Dermatophagoides pteronyssinus* genome and transcriptome reveals a wide range of novel allergens.

- Journal of Allergy and Clinical Immunology.2018 Jun 1;141(6):2268-71.
62. Dai X, Li RZ, Jiang ZB, Wei CL, Luo LX, Yao XJ*, Li GP* & **Leung EL***. Honokiol inhibits proliferation, invasion and induces apoptosis through targeting Lyn kinase in human lung adenocarcinoma cells. *Frontiers in Pharmacology*.2018 May 28;9:558.
 63. Wang QQ#, Xu JH#, Li Y, Huang JM, Jiang ZB, Wang YW, Liu L*, **Leung EL*** and Yao XJ*. Identification of a novel protein arginine methyltransferase 5 inhibitor in non-small cell lung cancer by structure-based virtual screening. *Frontiers in Pharmacology*.2018 Mar 1;9:173.
 64. Petrov JC, Wada M, Pinz KG, Yan LE, Chen KH, Shuai X, Liu H, Chen X, **Leung EL**, Salman H, Hagag N, Liu F, Jiang X, Ma Y. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. *Leukemia*.2018 Jun;32(6):1317-26.
 65. **Leung EL**#, Luo LX#, Liu ZQ, Wong VKW, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ*, Ward DC*, Liu L*. Inhibition of KRAS-dependent lung cancer cell growth by daltarasin: blockage of autophagy increases its cytotoxicity. *Cell Death & Disease*.2018 Feb 13;9(2):1-5.
 66. Fan XX#, **Leung EL**#, Xie Y, Liu ZQ, Zheng YF, Yao XJ, Lu LL, Wu JL, He JX, Yuan ZW, Fu JJ, Wei CL, Huang J, Xiao DK, Luo LX, Jiang ZB, Zhou YL, Kam RK, Liu L. Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases. *Antioxidants & Redox Signaling*.2018 Feb 10;28(5):339-57.
 67. Dai X, Li GP, Yang XQ, Wang XY, Wu J, **Leung EL***. Effects of Lyn kinase on EGFR signaling pathway in lung adenocarcinoma/Lyn. *China Oncology*.2018 Feb 7;28(1):43-9.
 68. Su X, Li T, Liu Z, Huang Q, Liao K, Ren R, Lu L, Qi X, Wang M, Chen J, Zhou H, **Leung EL**, Pan HD, Liu J, Wang H, Huang L, Liu L. Licochalcone A activates Keap1-Nrf2 signaling to suppress arthritis via phosphorylation of p62 at serine 349. *Free Radical Biology & Medicine*.2018 Feb 1;115:471-83.
 69. Lv S, Ji L, Chen B, Liu S, Lei C, Liu X, Qi X, Wang Y, **Leung EL**, Wang H, Zhang L, Yu X, Liu Z, Wei Q, Lu L. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. *Oncogene*.2018 Mar;37(10):1354-68.
 70. Pinz K, Yakaboski E, Jares A, Liu H, Firor A, Chen K, Wada M, Salman H, Tse W, Hagag N, Lan FS, **Leung EL**, Jiang S, Ma YP. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. *Oncotarget*.2017 Dec 22;8(68):112783.
 71. Li Y#, **Leung EL**#, Pan HD, Yao XJ, Huang QC, Wu M, Xu T, Wang YW, Cai J, Li RZ, W Liu, Liu L*. Identification of potential genetic causal variants for rheumatoid arthritis by whole-exome sequencing. *Oncotarget*.2017 Dec 19;8(67):111119.
 72. Xie C#, Li Y#, Li LL, Fan XX, Wang YW, Wei CL, Liu L*, **Leung EL***, Yao XJ*. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell

- Lung Cancer Cells. *Frontiers in Pharmacology*.2017 Nov 14;8:823.
73. Zhou H, Liu JX, Luo JF, Cheng CS, **Leung EL**, Li Y, Su XH, Liu ZQ, Chen TB, Duan FG, Dong Y, Zuo YH, Li C, Lio CK, Li T, Luo P, Xie Y, Yao XJ, Wang PX, Liu L. Suppressing mPGES-1 expression by sinomenine ameliorates inflammation and arthritis. *Biochemical Pharmacology*.2017 Oct 15;142:133-44.
 74. Chen X, Xie C, Fan XX, Jiang ZB, Wong VKB, Xu JH, Yao XJ*, Liu L*, **Leung EL***. Novel direct AMPK activator suppresses non-small cell lung cancer through inhibition of lipid metabolism. *Oncotarget*.2017 Nov 10;8(56):96089.
 75. Chen KH, Wada M, Pinz KG, Liu H, Shuai X, Chen X, Yan LE, Petrov JC, Salman H, Senzel L, **Leung EL**, Jiang X and Ma YP. A compound chimeric antigen receptor strategy for targeting multiple myeloma. *Leukemia*.2018 Feb;32(2):402-12.
 76. Wang QQ, Li Y, Xu JH, Wang YW, **Leung EL***, Liu L*, Yao XJ*. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations. *Scientific reports*.2017 Aug 18;7(1):1-1.
 77. Zhao L, **Leung EL**, Wang J, Li H, Che J, Liu L, Yao X*, Cao B*. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. *BMC pulmonary medicine*.2017 Dec 1;17(1):112.
 78. Luo LX, Li Y, Niu YZ, Fan XX, Xu JH, Liu L*, **Leung EL***, Yao XJ*. Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer. *MedChemComm*.2017;8(10):1914-8.
 79. Wong VKW, Zeng W, Chen J, Yao XJ, **Leung EL**, Wang QQ, Chiu P, Ko BCB, Law BYK. Tetrandrine, an Activator of Autophagy, Induces Autophagic Cell Death via PKC- α Inhibition and mTOR-Dependent Mechanisms. *Frontiers in Pharmacology*.2017 Jun 8;8:351.
 80. Li XG, Tang S, Wang QQ, **Leung EL**, Jin HY, Huang YZ, Liu J, Geng MY, Huang M, Yuan ST, Yao XJ, Ding J. Identification of Epigallocatechin-3-Gallate as an Inhibitor of Phosphoglycerate Mutase 1. *Frontiers in Pharmacology*.2017 May 30;8:325.
 81. Luo LX, Li Y, Liu ZQ, Fan XX, Duan FG, Li RZ, Yao XJ*, **Leung EL***, Liu L*. Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. *Frontiers in Pharmacology*.2017 Apr 11;8:199.
 82. Yang N, **Leung EL**, Liu CB, Li L, Eguether T, Yao XJ, Jones E, Norris D, Liu A, Clark R, Roop DR, Pazour GJ, Shroyer KR, Chen J. INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma. *Oncogene*.2017 Aug;36(35):4997-5005.
 83. Zong XX, Yan G Y, Wu JL, **Leung EL**, Zhou H, Li N, Liu L. New C 19 -diterpenoid alkaloids from the parent roots of *Aconitum carmichaelii*. *Tetrahedron letters*.2017 Apr 19;58(16):1622-6.
 84. Luo LX, Fan XX, Li Y, Peng X, Ji YC, Hsiao WW, Liu L*, **Leung EL***, XJ* Yao. Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in

- non-small cell lung cancer cells. *MedChemComm*.2017;8(3):621-4.
85. Law BY, Gordillo-Martínez F, Qu YQ, Zhang N, Xu SW, Saul Coghi P, Mok SW, Guo JR, Zhang W, **Leung EL**, Fan XX, Wu AG, Chan WK, Yao XJ, Wang JR, Liu L, Wong VK. Thalidezine, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death. *Oncotarget*.2017 May 2;8(18):30077.
 86. Chen K, Wada M, Pinz K, Liu H, Lin KW, Jares A, Firor A, Shuai X, Salman H, Golightly M, Lan FS, Senzel L, **Leung EL**, X Jiang, Ma YP. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. *Leukemia*.2017 Oct;31(10):2151-60.
 87. Liang Y, Wu JL, Li X, Guo MQ, **Leung EL**, Zhou H, Liu L, Li N. Anti-cancer and anti-inflammatory new vakognavine-type alkaloid from the roots of *Aconitum carmichaelii*. *Tetrahedron letters*.2016 Dec 28;57(52):5881-4.
 88. **Leung EL**, Clementi E, Wong WS. Advanced technologies charting a new path for traditional Chinese medicine drug discovery. *Pharmacological Research*.2017 Mar;117:65.
 89. Li X#, Fan XX#, Jiang ZB, Loo WTY, Yao XJ, **Leung EL***, Chow LWC*, Liu L*. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway. *Pharmacological Research*.2017 Jan 1;115:45-55.
 90. Yu J, Zhang Y, **Leung EL**, Liu L, Yang F, Yao X. Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. *Journal of hematology & oncology*.2016 Dec 1;9(1):111.
 91. Wong VK#, Law YK#, Yao XJ, Chen X, Xu SW, Liu L*, **Leung EL***. Advanced research technology for discovery of new effective compounds from Chinese herbal medicine and their molecular targets. *Pharmacological Research*.2016 Sep 1;111:546-55.
 92. Wang MF#, Li RZ#, Li Y, Cheng XQ, Yang J, Chen W, Fan XX, Pan HD, Yao XJ, RT XQ, Liu L*, **Leung EL***, Tang YJ*. Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population. *Journal of thoracic disease*.2016 Aug;8(8):2203.
 93. Xu SW, Law BY, Mok SW, **Leung EL**, Fan XX, Coghi PS, Zeng W, Leung CH, Ma DL, Liu L, Wong VKB. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. *International Journal of Oncology*.2016 Oct 1;49(4):1576-88.
 94. Chan CM, Chu H, Zhang AJ, **Leung EL**, Sze KH, Kao RY, Chik KK, To KK, Chan JW, Chen H, Jin DY, L Liu, Yuen KY*. Hemagglutinin of influenza A virus binds specifically to cell surface nucleolin and plays a role in virus internalization. *Virology*.2016 Jul 1;494:78-88.
 95. Huang J#, Fan XX#, He JX#, Pan H, Li RZ, Huang LY, Jiang ZB, Yao XJ, Liu L, **Leung EL***, He JX*. SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma. *Oncotarget*.2016 Jun 28;7(26):39970.
 96. Jiang ZB#, Huang J#, Xie C, Li X, Liu L, He J, Pan H, Huang L, Fan XX, Yao

- XJ, Xie Y, Li N, Liu L, He JX*, **Leung EL***. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. *Oncology reports*.2016 Jul 1;36(1):365-75.
97. Liang Y, Wu JL, **Leung EL**, Zhou H, Liu ZQ, Yan GY, Liu Y, Liu L*, Li N*. Identification of Oxygenated Fatty Acid as a Side Chain of Lipo-Alkaloids in *Aconitum carmichaelii* by UHPLC-Q-TOF-MS and a Database. *Molecules*.2016 Apr;21(4):437.
 98. Zhang YZ#, Chen X#, Fan XX, He JX, Huang J, Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, Liu L*, **Leung EL***. Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of alpha-Tubulin and Inhibition of Microtubule Formation. *Molecules*.2016 Mar;21(3):374.
 99. **Leung EL**, Fan XX, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin PC, Liu L. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation. *Antioxidants & Redox Signaling*.2016 Feb 10;24(5):263-79.
 100. Wong VK, Dong H, Liang X, Bai LP, Jiang ZH, Guo Y, Kong AN, Wang R, Kam RK, Law BY, Hsiao WW, Chan KM, Wang J, Chan RW, Guo J, Zhang W, Yen FG, Zhou H, **Leung EL**, Yu Z, Liu L. Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells. *Oncotarget*.2016 Mar 1;7(9):9907.
 101. Lu LL, Liu XH, **Leung EL**, Wang Y, Shi J, Hu M, Liu L, Liu ZQ. The bioavailability barrier and personalized traditional Chinese medicine. *Science*.2015;350(6262):S79-81.
 102. Fan XX, Yao XJ, Xu SW, Wong VK, He JX, Ding J, Xue WW, Mujtaba T, Michelangeli F, Huang M, Huang J, Xiao DK, Jiang ZB, Zhou YL, Kam RK, Liu L*, **Leung EL***. (Z)3,4,5,4'-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level. *Scientific reports*.2015 Nov 6;5:16348.
 103. Yuan ZW, **Leung EL**, Fan XX, Ma WZ, Liu L, Xie Y. Quantitative evaluation of berberine subcellular distribution and cellular accumulation in non-small cell lung cancer cells by UPLC-MS/MS. *Talanta*.2015 Nov 1;144:20-8.
 104. Li T, Wong VK, Jiang ZH, Jiang SP, Liu Y, Wang TY, Yao XJ, Su XH, Yan FG, Liu J, **Leung EL**, Yi XQ, Wong YF, Zhou H, Liu L. Mutation of cysteine 46 in IKK-beta increases inflammatory responses. *Oncotarget*.2015 Oct 13;6(31):31805.
 105. Gu WY, Li N, **Leung EL**, Zhou H, Yao XJ, Liu L, Wu JL. Rapid identification of new minor chemical constituents from *Smilacis Glabrae* Rhizoma by combined use of UHPLC-Q-TOF-MS, preparative HPLC and UHPLC-SPE-NMR-MS techniques. *Phytochemical analysis*.2015

Nov;26(6):428-35.

106. Liu L, Liu L, **Leung EL**, Cooney AJ, Chen C, Rosengart TK, Ma YP, Yang JC. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells. *Journal of biological chemistry*.2015 Apr 24;290(17):10599-609.
107. Wang R, Zhang CY, Bai LP, Pan HD, Shu LM, Kong AN, **Leung EL**, Liu L, Li T. Flavonoids derived from liquorice suppress murine macrophage activation by up-regulating heme oxygenase-1 independent of Nrf2 activation. *International immunopharmacology*.2015 Oct 1;28(2):917-24.
108. Gu WY, Li N*, **Leung EL**, Zhou H, Luo GA, L Liu, Wu JL*. Metabolites software-assisted flavonoid hunting in plants using ultra-high performance liquid chromatography-quadrupole-time of flight mass spectrometry. *Molecules*.2015 Mar;20(3):3955-71.
109. Yang ZF#, **Leung EL**#, Liu L, ZH Jiang, Zhong NS*. Developing influenza treatments using traditional Chinese medicine. *Science*.2015;347(6219):S35-7.
110. **Leung EL**, Wong VK, Jiang ZH, T Li, Liu L*. Integrated network-based medicine: The role of traditional Chinese medicine in developing a new generation of medicine. *Science*.2014;346(6216):S16-8.
111. Fan XX, Li N, Wu JL, Zhou YL, He JX, Liu L, **Leung EL***. Celestrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation. *Molecules*.2014 Mar;19(3):3508-22.
112. Wu JL, **Leung EL**, Zhou H, L Liu, Li N. Metabolite analysis of toosendanin by an ultra-high performance liquid chromatography-quadrupole-time of flight mass spectrometry technique. *Molecules*.2013 Oct;18(10):12144-53.
113. Wang TY, Zhou H, Wong YF, Wu PK, Hsiao WL, **Leung EL***, Liu L*. The Predicted Proteomic Network Associated with the Antiarthritic Action of Qingfu Guanjieshu in Collagen-II-Induced Arthritis in Rats. *Evidence-Based Complementary and Alternative Medicine*.2013 Jan 1;2013.
114. **Leung EL**, Cao ZW, Jiang ZH, Zhou H, Liu L. Network-based drug discovery by integrating systems biology and computational technologies. *Briefings in bioinformatics*.2013 Jul 1;14(4):491-505.
115. Liu L, **Leung EL**, Tian X. PERSPECTIVE The clinical trial barriers. *Nature*.2011 Dec;480(7378):S100-.
116. Wong DW, **Leung EL**, Wong SK, Tin VP, Sihoe AD, Cheng LC, Au JS, Chung LP, Wong MP. A novel KIF5B-ALK variant in nonsmall cell lung cancer. *Cancer*.2011 Jun 15;117(12):2709-18.
117. **Leung EL**, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y, Wong MP. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. *PloS one*.2010 Nov 19;5(11):e14062.
118. **Leung EL**, Wong JC, Johlfs MG, Tsang BK, Fiscus RR. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. *Molecular Cancer*

Research.2010 Apr 1;8(4):578-91.

119. Gai H, **Leung EL**, Costantino PD, Aguila JR, Nguyen DM, Fink LM, Ward DC, Ma Y. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. *Cell biology international*.2009 Nov 1;33(11):1184-93.
120. Tam IY#, **Leung EL**#, Tin VP, Chua DT, Sihoe AD, Cheng LC, Chung LP, Wong MP. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. *Molecular cancer therapeutics*.2009 Aug 1;8(8):2142-51.
121. **Leung EL**, Tam IY, Tin VP, Chua DT, Sihoe AD, Cheng LC, Ho JC, Chung LP, Wong MP. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. *Molecular Cancer Research*.2009 Jun 1;7(6):923-32.
122. Wong DW, **Leung EL**, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer*.2008 Dec 1;109(Supplement):77-86.
123. **Leung EL**, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. *British journal of cancer*.2008 Jun;98(11):1803-9.

出版物:

1. Ahmed Y. Ali, Lee Farrand, Ji Young Kim, Sanguine Byun, Elaine Lai-Han Leung, Hyong Joo Lee and Benjamin K. Tsang. Chapter for “New Perspectives in Chemoresistant Ovarian Cancer”, *Ovarian Toxicology*. 2012 (Accepted)
2. Ronald R. Fiscus, Elaine L. Leung, Janica C. Wong and Mary G. Johlfs. Chapter for “ Ovarian Cancer/Book 1 ”, ed. Samir Farghaly, INTECH Open Access Publisher, Rijeka, Croatia, Accepted – August 16, 2011, Scheduled Publication – October 2011. Nitric oxide/protein kinase G-Ia promotes c-Src activation, proliferation and chemoresistance in ovarian cancer

專利:

1. A novel treatment of Gefitinib-resistant non-small-cell lung cancer using sanguinarine. **Leung EL**, Fan XX, Liu L. (US patent provisional filed; Australia patent awarded for 8 years-2014100435)
2. The new application of an alkaloid derived from a Chinese herbal for treatment of cancer by inhibiting cholesterol synthesis and fatty acid oxidation. **Leung EL**, Fan XX, Liu L, Wu JL. (US patent provisional filed; Australia patent awarded for 8 years-2014100831)
3. Methods for Novel Drug Discovery, Treatment and Selective Targeting for Gefitinib-Resistant Non-Small-Cell Lung Cancer Harboring T790M Mutation. **Leung EL**, Liu L and Fan XX (US patent awarded-US 9439898 B2; Australia patent awarded for 8 years-2014100614)
4. The application of (Z) 3,4,5,4'-tetramethoxystilbene (TMS) in Gefitinib-resistant non-small-cell lung cancer cells. **Leung EL**, Fan XX, Liu L and Jiang ZB (US patent-awarded-9597299; Australia patent awarded for 8 years-2015100187)

5. Oncogene ROS1 kinase inhibitor. Yao XJ, **Leung EL**, Luo LX, Zhou YL and Liu L. (US patent awarded-9526722B1; Australia patent awarded for 8 years-2015100840)
6. Identification of new AMPK activator for treatment of lung cancer. **Leung EL**, Yao XJ, Wong VKW, Liu L and Chen X (US patent awarded-US 9364469 B1; Australia patent awarded for 8 years- 2015101612)
7. Identification of New Chemical Structure as AMPK Activator for Treatment at EGFR^{L858R/T790M} Double Mutation Non-Small Cell Lung Cancer. (Method to treat lung cancer) Liu L, **Leung EL**, Yao XJ, Wong VKW and Chen Ci (US patent awarded- Patent No. 9,855,250 B1)
8. Identification of new role of mitoxantrone as a direct ROS1 oncogenic kinase inhibitor. Yao XJ, **Leung EL**, Luo LX, Hsiao WL and Liu L (US patent awarded for 8 years-US 9522125 B1; Australia patent awarded for 8 years- 2015101712)
9. C498-0065, a novel ROS1 inhibitor, demonstrates potent inhibition activity against ROS1 fusion oncokinasase. Yao XJ, **Leung EL**, Luo LX and Liu L (US patent awarded-9782400B2; Australia patent awarded for 8 years- 2015101598)
10. PDEd inhibitor for the treatment of cancer. Yao XJ, **Leung EL**, Luo LX and Liu L (US patent awarded US 2017/0135979A1; Australia patent awarded for 8 year-2015101666)
11. ALK kinase inhibitor and its use. Yao XJ, **Leung EL**, Luo LX and Liang L (US patent filed; Australia patent awarded for 8 year- 2016101467)
12. Hydroxynaphthoquinone compounds (shikonin) for treating of non-small cell lung cancer. Liu L, **Leung EL**, Li X, Fan XX (US patent awarded 15/186,795; Australia patent awarded for 8 year- 2016100891)
13. Methods for treating lung cancer (PKM2 activator). Liu L, **Leung EL**, Yao XJ and Li RZ (US patent awarded-9744145, Australia patent awarded for 8 year-2017100105)
14. Methods of identifying a gene associated with a disease or pathological condition of the disease. Liu L, **Leung EL**, Yao XJ, Li Y and Pan HD.(US Patent No. 15/647,414 field on 12 July 2017; Australia patent awarded for 8 year-2017100960)
15. Bufadienolide for treatment of non-small cell lung cancer. Liu L, **Leung EL**, Yao XJ, Li RZ and Fan XX. (US patent field, Australia awarded for 8 years-2017100644)
16. Method for treating cancer (BPTF small molecule). **Leung EL**, Xiao XJ, Liu L, Xu JH, Li Y and Wang QQ (US patent field, Australia patent awarded for 8 years-2018100077)
17. Method of treating cancer (PRMT5). Yao XJ, **Leung EL**, Liu L, Wang QQ, Xu JH & Li Y. (US patent filed, Australia patent awarded for 8 years-2018100078)
18. Method of treating cancer (KRAS SOS inhibitor 1). Yao XJ, **Leung EL**, Liu L, Fan XX, Xie C. (US patent awarded 15/84046).
19. Method of treating lung cancer (KRAS SOS inhibitor 2). Yao XJ, **Leung EL**, Liu L, Fan XX, Xie C. (US patent awarded 15/84047)
20. Combinational treatment of Ras-positive diseases with PDE delta inhibitor and direct autophagy inhibitor. Liang Liu, Ward DC, **Leung EL**, Yao XJ, Wong VKW, Luo LX. (US patent awarded US9861623B1)

研究項目

2020-2023	埃爾文內爾博士生物物理與中醫藥研究室
2019-2022	調整腸道微生態增強 PD1 抗體治療非小型細胞肺癌效果的新策略
2018	中药靶向 T 淋巴细胞调节肿瘤代谢重塑抗肿瘤免疫的分子机制

2016-2019	活性氧類與蛋白酶氧化還原對非小細胞型肺癌的調控與藥物干預
2015-2016	Next SeqTM 500 Next generation DNA sequencer
2015-2016	Next SeqTM 500 Next generation DNA sequencer work station
2014-2015	肺腺癌耐藥代謝生物標誌物鑒定與基於網絡調節藥物的發現
2013-2015	Investigation on the novel candidate anti-cancer drug from Chinese herbal medicine by modulating metabolic profiles of cancer cells

學術機構及社會任職

- 澳門生命科學學會/名譽顧問
- 世界中醫藥學會聯合會中醫免疫學專業委員會/常務理事

專業資格認證及獎項

2020 青年岐黃學者

2018 教育部高等學校自然科學獎一等獎

2018 中珠醫療生命科學獎-優秀醫藥教師獎 (科研獎特等獎)

2017 中珠醫療生命科學獎-優秀醫藥教師獎 (科研獎特等獎)

2015 年獲教育部高等學校自然科學類一等獎

2014 年獲澳門科學技術自然科學類一等獎

2013 年獲中銀學術研究優秀獎